ASCO Annual Meeting: Hematology | Conference

Samer A. Srour, MB, ChB, MS, Discusses Umbilical Cord Blood-Derived Natural Killer Cell Combination as a Potential Strategy for High-Risk Multiple Myeloma
July 29, 2022

Elotuzumab, lenalidomide, high-dose melphalan, as well as umbilical cord blood–derived natural killer cells and autologous stem cell transplant demonstrated tolerability and improved transplant outcomes for high-risk multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, Talks Benefits of Evaluating Elotuzumab Plus RVd in Newly Diagnosed Myeloma
July 17, 2022

Saad Z. Usmani, MD, MBA, FACP, spoke about the safety profile of standard triplet therapy with or without elotuzumab for patients with newly diagnosed, high-risk multiple myeloma in the phase 3 SWOG 1211 trial and how results of this trial may be used in future datasets to inform treatment in this setting.

Ola Landgren, MD, PhD, Highlights How DETERMINATION Trial Results Inform Use of RVd/Transplant in Newly Diagnosed Myeloma
July 16, 2022

C. Ola Landgren, MD, PhD, discusses progression-free survival data from the phase 3 DETERMINATION trial examining lenalidomide, bortezomib, and dexamethasone with or without autologous stem cell transplant plus continuous lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Paul G. Richardson, MD, Highlights Benefits of Continuous Lenalidomide Maintenance Vs ASCT in Newly Diagnosed Myeloma
July 11, 2022

At 2022 ASCO, Paul G. Richardson, MD, dives into results of the DETERMINATION study, which examined triplet therapy with lenalidomide plus either lenalidomide maintenance until progression or autologous stem transplantation in newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, Discusses Results of SWOG 1211 Examining RVd Plus Elotuzumab in Newly Diagnosed Myeloma
July 09, 2022

Saad Z. Usmani, MD, MBA, FACP, discusses the use of lenalidomide, bortezomib, and dexamethasone with or without elotuzumab for newly diagnosed, high-risk multiple myeloma.

Paul G. Richardson, MD, Talks Rationale for Investigating Lenalidomide Maintenance Until Progression in Newly Diagnosed Myeloma
July 07, 2022

At 2022 ASCO, Paul G. Richardson, MD, reviewed the rationale of the phase 3 DETERMINATION study that set out to determine the benefit of lenalidomide maintenance with or without autologous stem transplantation in newly diagnosed multiple myeloma.

Phase 2 Alliance A059102 Trial Will Assess the Efficacy of Duvelisib/Azacitidine Plus CHOP/CHOEP for Peripheral T-Cell Lymphoma
July 01, 2022

In the phase 2 Alliance A059102 trial, patients with treatment-naïve CD30-negative peripheral T-cell lymphoma will be treated with duvelisib and azacitidine plus CHOP/CHOEP chemotherapy.

Samer A. Srour, MB, ChB, MS, Reviewed Findings of CB-NK Cells and Elotuzumab Regimen in High-Risk Multiple Myeloma
June 30, 2022

A phase 2 study investigated the use of cord blood–derived natural killer cells plus elotuzumab, lenalidomide, and melphalan with autologous stem cell transplant for patients with high-risk multiple myeloma.

Ola Landgren, MD, PhD, Discusses IFM 2009 and DETERMINATION Trials of RVd and Lenalidomide Maintenance in Myeloma
June 24, 2022

C. Ola Landgren, MD, PhD, highlights the rationale for the phase 3 DETERMINATION trial, assessing the use of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant and lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Follow-up Data Show Continuous Advantage of Zanubrutinib Over Ibrutinib for MYD88+ Waldenström Macroglobulinemia
June 12, 2022

Follow-up results of the phase 3 ASPEN trial comparing zanubrutinib with ibrutinib in patients with Waldenström macroglobulinemia were presented at 2022 ASCO.